US · VTRS · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Viatris Inc. (VTRS) intrinsic value and stock valuation
$19.63as of 2026-11-21 · Mkt cap 20.55B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Viatris Inc. DCF and intrinsic value
InvestorsCraft values VTRS with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from VTRS’s statements →
Viatris Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Roivant Sciences Ltd. (ROIV) $38.66
- Moderna, Inc. (MRNA) $195.00
- Neurocrine Biosciences, Inc. (NBIX) $150.57
- BridgeBio Pharma, Inc. (BBIO) $76.03
- Baxter International Inc. (BAX) $25.39
- Elanco Animal Health Incorporated (ELAN) $25.74
- Dr. Reddy's Laboratories Limited (RDY) $14.89
- Ionis Pharmaceuticals, Inc. (IONS) $26.58
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $14.3B | $14.7B | $15.4B | $16.3B | $17.9B |
| Operating income | -$-2.66B | $10.1M | $766.2M | $1.61B | -$-34M |
| Net income | -$-3.51B | -$-634.2M | $54.7M | $2.08B | -$-1.27B |
| EPSd | -$-3M | -$-531.47K | $45.3K | $1.71M | -$-1.05M |
| Operating cash flow | $2.32B | $2.3B | $2.8B | $3B | $3.02B |
| Capital expenditure | -$-378.8M | -$-326M | -$-474.5M | -$-489.4M | -$-509.4M |
| Free cash flow | $1.94B | $1.98B | $2.33B | $2.51B | $2.51B |
| Total assets | $37.2B | $41.5B | $47.7B | $50B | $54.8B |
| Total debt | $14.7B | $14.3B | $18.4B | $19.5B | $23.4B |
| Net debt | $13.4B | $13.6B | $17.4B | $18.3B | $22.7B |
| Total equity | $14.7B | $18.6B | $20.5B | $21.1B | $20.5B |
| Cash and short-term investments | $1.45B | $1.09B | $1.18B | $1.47B | $935M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $14.3B | $14.7B | $15.4B | $16.3B | $17.9B |
| Cost of revenue | $9.29B | $9.12B | $8.99B | $9.77B | $12.3B |
| Gross profit | $5.01B | $5.62B | $6.44B | $6.5B | $5.58B |
| Research and development expenses | $965.9M | $808.7M | $805.2M | $662.2M | $681M |
| Selling, general and administrative expenses | $3.79B | $4.43B | $4.65B | $4.18B | $4.53B |
| Other expenses | $2.92B | $379.2M | $217.1M | $40.8M | $399.3M |
| Operating expenses | $7.68B | $5.61B | $5.67B | $4.88B | $5.61B |
| Cost and expenses | $17B | $14.7B | $14.7B | $14.6B | $17.9B |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $471.3M | $550M | $573.1M | $592.4M | $636.2M |
| Depreciation and amortization | $2.8B | $2.89B | $2.74B | $3.03B | $4.51B |
| Ebitda | -$-395.4M | $2.82B | $3.52B | $6.43B | $4.48B |
| Operating income | -$-2.66B | $10.1M | $766.2M | $1.61B | -$-34M |
| Total other income/expenses, net | -$-1B | -$-633.3M | -$-563.3M | $1.2B | -$-630.4M |
| Income before tax | -$-3.67B | -$-623.2M | $202.9M | $2.81B | -$-664.4M |
| Income tax expense | -$-150.1M | $11M | $148.2M | $734.6M | $604.7M |
| Net income | -$-3.51B | -$-634.2M | $54.7M | $2.08B | -$-1.27B |
| Weighted average shares outstanding | $1.17B | $1.19B | $1.2B | $1.21B | $1.21B |
| Weighted average diluted shares outstanding | $1.17B | $1.19B | $1.21B | $1.22B | $1.21B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.45B | $1.09B | $1.18B | $1.47B | $935M |
| Net receivables | $3.35B | $3.52B | $4.04B | $4.14B | $4.27B |
| Inventory | $4B | $3.85B | $3.47B | $3.52B | $3.98B |
| Total current assets | $9.22B | $9.52B | $13B | $10.6B | $10.9B |
| Property, plant and equipment, net | $2.89B | $2.92B | $3.01B | $3.28B | $3.48B |
| Goodwill and intangible assets | $21.9B | $26.2B | $29B | $33B | $38.2B |
| Long-term investments | $815M | $1.35B | $1.14B | $1.09B | $81.4M |
| Total non-current assets | $28B | $32B | $34.7B | $39.4B | $43.9B |
| Total assets | $37.2B | $41.5B | $47.7B | $50B | $54.8B |
| Accounts payable | $1.29B | $1.36B | $1.38B | $1.16B | $1.06B |
| Short-term debt | $2.04B | $87.7M | $2.02B | $1.33B | $3.44B |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $7.09B | $5.78B | $7.78B | $6.75B | $9.88B |
| Long-term debt | $12.7B | $14.2B | $16.4B | $18.2B | $19.9B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $15.4B | $17.1B | $19.4B | $22.2B | $24.5B |
| Capital lease obligations | $178.1M | $266.4M | $248.4M | $262M | $287.6M |
| Total liabilities | $22.5B | $22.9B | $27.2B | $28.9B | $34.4B |
| Common stock | $12.5M | $12.3M | $12.2M | $12.1M | $12.1M |
| Retained earnings | -$-388.3M | $3.42B | $4.64B | $5.18B | $3.69B |
| Accumulated other comprehensive income (loss) | -$-2.71B | -$-3.21B | -$-2.75B | -$-2.76B | -$-1.74B |
| Total equity | $14.7B | $18.6B | $20.5B | $21.1B | $20.5B |
| Total investments | $921.4M | $1.7B | $1.33B | $1.3B | $315.2M |
| Total debt | $14.7B | $14.3B | $18.4B | $19.5B | $23.4B |
| Net debt | $13.4B | $13.6B | $17.4B | $18.3B | $22.7B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-3.51B | -$-634.2M | $54.7M | $2.08B | -$-1.27B |
| Depreciation and amortization | $2.8B | $2.71B | $2.74B | $3.03B | $4.51B |
| Stock-based compensation | $177.7M | $146.1M | $180.7M | $116.4M | $111.2M |
| Change in working capital | -$-2.5B | -$-318.6M | -$-711.3M | -$-922.6M | -$-1.8B |
| Accounts receivable | $334.6M | $300.1M | $78.6M | -$-240.3M | $59.3M |
| Inventory | -$-106.4M | -$-723.4M | -$-613.3M | -$-259.5M | -$-427.6M |
| Accounts payable | -$-168M | $36M | $314.7M | $170.2M | -$-70.4M |
| Net cash provided by operating activities | $2.32B | $2.3B | $2.8B | $3B | $3.02B |
| Investments in property, plant and equipment | -$-378.8M | -$-326M | -$-377M | -$-489.4M | -$-509.4M |
| Acquisitions, net | $0.00 | -$-350M | -$-667.7M | $0.00 | $277M |
| Net cash used for investing activities | -$-427.7M | $1.8B | -$-764.1M | $1.47B | -$-117.8M |
| Common stock issued | $2.6M | $2.5M | $3.1M | $3.3M | $0.00 |
| Common stock repurchased | -$-500.5M | -$-250M | -$-250M | $0.00 | -$-17.4M |
| Dividends paid | -$-561.2M | -$-574.8M | -$-575.6M | -$-581.6M | -$-399M |
| Net cash used for financing activities | -$-1.29B | -$-4.33B | -$-2.3B | -$-3.88B | -$-3.01B |
| Net change in cash | $611.9M | -$-257.5M | -$-268.9M | $556.3M | -$-143.8M |
| Cash at end of period | $1.35B | $736.1M | $993.6M | $1.26B | $706.2M |
| Operating cash flow | $2.32B | $2.3B | $2.8B | $3B | $3.02B |
| Capital expenditure | -$-378.8M | -$-326M | -$-474.5M | -$-489.4M | -$-509.4M |
| Free cash flow | $1.94B | $1.98B | $2.33B | $2.51B | $2.51B |
Line items
Line items
Line items
About Viatris Inc.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
- CEO
- Scott Andrew Smith
- Employees
- 30K
- Beta
- 0.90
Explore
Frequently asked questions
What is the intrinsic value of Viatris Inc. (VTRS)?
Viatris Inc. (VTRS) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is VTRS undervalued?
VTRS trades at a price of $19.63 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.